Showing results (101-110 of 656) with videos related to
Sort By:
Pageof 66
Journal of Pharmacokinetics and Pharmacodynamics|October 10, 2018
The use of PBPK modeling across the pediatric age range using propofol as a caseRobin Michelet, Jan Van Bocxlaer, Karel Allegaert, et al.European Journal of Pediatrics|November 5, 2011
Educational paper: Retinopathy of prematurityIngele Casteels, Catherine Cassiman, Joachim Van Calster, et al.Expert Review of Clinical Pharmacology|February 10, 2018
Drug evaluation studies in neonates: how to overcome the current limitationsKarel Allegaert, Anne Smits, John N van den AnkerFrontiers in Pharmacology|June 2, 2020
A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in NeonatesAnne Smits, Pieter Annaert, Steven Van Cruchten, et al.Expert Opinion on Drug Metabolism & Toxicology|May 12, 2015
Neonatal medicines research: challenges and opportunitiesJanko Samardzic, Mark A Turner, Ralph Bax, et al.Current Pharmaceutical Design|September 2, 2015
Dosing Guidelines of Aminoglycosides in Neonates: A Balance Between Physiology and FeasibilityKarel Allegaert, Veerle Cossey, John N van den AnkerCurrent Pharmaceutical Design|September 2, 2015
Neonatal Formulations: The Need for a Tailored, Knowledge Driven ApproachKarel Allegaert, Katrien Cosaert, John N van den AnkerDrug Metabolism Letters|April 10, 2009
Covariates of amikacin clearance in neonates: the impact of postnatal age on predictabilityKarel Allegaert, Isabelle Scheers, Veerle Cossey, et al.Pediatric Nephrology (Berlin, Germany)|November 13, 2013
The interplay between drugs and the kidney in premature neonatesMichiel F Schreuder, Ruud R G Bueters, Karel AllegaertCurrent Pharmaceutical Design|September 28, 2017
Developmental Pharmacokinetics in Neonates: Maturational Changes and BeyondKarel Allegaert, Paola Mian, John N van den AnkerPageof 66